JD Retail is leveraging AI, low prices and ecosystem scale to capture China's consumer rebound in 2025.

It can pay substantial dividends to follow the smart money billionaires in certain stocks.

OpenAI recently announced a $200 million deal with the U.S. Department of Defense (https://techcrunch.com/2025/06/17/openais-200m-dod-contract-could-squeeze-frenemy-microsoft/) , which has us wondering: Could this further strain the company's relationship with its biggest backer, Microsoft? After all, there have been numerous reports about growing tensions (https://techcrunch.com/2025/06/16/the-cracks-in-the-openai-microsoft-relationship-are-reportedly-widening/) between the two companies, particularly as they become more competitive over enterprise deals (https://techcrunch.com/2025/05/11/microsoft-and-openai-may-be-renegotiating-their-partnership/).

Though Wednesday was a flat day for the stock, Advanced Micro Devices Inc. NASDAQ: AMD looks likely to continue adding to a rally that has logged an impressive 65% since April. The strong uptrend has been characterized by a run of higher lows and higher highs, exactly what Wall Street wants to see after months of concerning underperformance.

The Investment Committee debate how to trade some of their stocks on the move.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 24, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Napco Security Technologies, Inc. (“Napco” or the “Company”) (NASDAQ: NSSC) securities between February 5, 2024, to February 3, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON NAPCO SECURITY TECHNOLOGIES, INC. (NSSC), CLICK HE.

On today's Catalysts, host Brad Smith dives into market shifts, AI trends, and retirement risks with expertise from a wide range of guests. Jeremy Schwartz, Chief Investment Officer at WisdomTree Global, breaks down how investors are adjusting portfolios amid tariff tensions, geopolitical conflicts, and anticipated interest rate cuts.

Dell Technologies CSG revenues increase 5% year over year as Windows 11 upgrades and AI-ready PCs fuel demand amid a recovering market.

Zymeworks (ZYME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ponce Financial (PDLB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AptarGroup (ATR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

United Bankshares (UBSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Does Vizsla Silver Corp. (VZLA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Universal Technical (UTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Noah Holdings (NOAH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Newmont (NEM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Rivian Automotive (RIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

DAVENPORT, Iowa, June 20, 2025 (GLOBE NEWSWIRE) -- Nathan Bekke, Operating Vice President and Vice President of Audience Strategy, has been named Chief Operating Officer of Lee Enterprises, Incorporated (NASDAQ:LEE).

DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that, in June, it submitted its complete response to the previously announced clinical hold of its Investigational New Drug Application (IND) for GH001 to the U.S. Food and Drug Administration (FDA).